Alembic Pharmaceuticals Limited (APLLTD) AI Stock Analysis

• Market Cap: ₹192.10B
• Dividend Yield: 1.15%
• Average Volume (3M): 3.29K
• Price to Earnings (P/E): 31.9
• Beta (1Y): 0.93
• Revenue Growth: 8.20%
• EPS Growth: -4.26%
• Country: IN
• Employees: 14,858
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.90
• Shares Outstanding: 196,563,130
• 10 Day Avg. Volume: 4,286
• 30 Day Avg. Volume: 3,288
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹922.50
• Price Target Upside: -5.61% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: ₹1,021.00 ▲(4.47% Upside)

Alembic Pharmaceuticals' overall score is driven by strong financial performance in terms of revenue growth and profitability, but tempered by cash flow challenges and high valuation. Technical indicators suggest a neutral market sentiment.

Alembic Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, and anti-diabetic. In addition, it exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

How the Company Makes Money

Alembic Pharmaceuticals Limited makes money primarily through the sale of its pharmaceutical products, which include both generic formulations and active pharmaceutical ingredients (APIs). The company generates revenue from domestic sales in India as well as through exports to international markets such as the United States, Europe, and other regions. Key revenue streams include the mass production and distribution of generic drugs, which are sold to wholesalers, pharmacies, and healthcare providers. Additionally, APLLTD engages in contract manufacturing and out-licensing arrangements, where it partners with other pharmaceutical companies to produce or distribute products, enhancing its market reach and distribution capabilities. The company also invests in research and development to innovate and expand its product portfolio, ensuring a steady pipeline of new and competitive products to sustain its revenue growth.

Alembic Pharmaceuticals Limited Financial Statement Overview

Summary

Alembic Pharmaceuticals shows strong revenue growth and profitability improvements, but faces challenges with cash flow management and rising leverage. Continued focus on cost control and cash conversion is crucial.

Income Statement

Alembic Pharmaceuticals shows strong gross profit margins over the years, with a notable improvement in revenue and EBIT margins in the recent period. However, the net profit margin has experienced some fluctuations, indicating potential cost management issues. The consistent revenue growth rate is a positive indicator of the company's expanding market presence.

Balance Sheet

The balance sheet reveals a healthy equity base, reflected in a strong equity ratio. The debt-to-equity ratio increased in the latest period, which could indicate rising leverage and potential risk. However, the return on equity remains robust, suggesting efficient use of shareholders' funds.

Cash Flow

The cash flow statement highlights a decline in free cash flow due to increased capital expenditures. The operating cash flow to net income ratio is lower, indicating less cash generation from operations. The negative free cash flow to net income ratio suggests challenges in converting profits into cash.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.72B	66.72B	56.53B	62.29B	52.32B	52.76B
Gross Profit	44.30B	48.79B	39.44B	22.69B	35.09B	37.55B
EBITDA	10.51B	10.08B	7.11B	9.62B	9.25B	15.68B
Net Income	5.83B	5.83B	3.42B	6.16B	5.21B	11.46B
Balance Sheet
Total Assets	77.73B	77.73B	61.83B	64.46B	71.22B	67.09B
Cash, Cash Equivalents and Short-Term Investments	901.00M	901.00M	921.20M	1.20B	610.90M	2.85B
Total Debt	12.57B	12.57B	7.22B	5.13B	7.17B	5.84B
Total Liabilities	25.83B	25.83B	18.12B	16.27B	18.84B	16.42B
Stockholders Equity	51.91B	51.91B	43.70B	48.18B	52.38B	51.28B
Cash Flow
Free Cash Flow	0.00	-4.76B	2.81B	4.76B	1.27B	8.04B
Operating Cash Flow	0.00	879.70M	7.24B	8.03B	5.52B	14.63B
Investing Cash Flow	0.00	-5.68B	-4.48B	-3.21B	-3.72B	-8.39B
Financing Cash Flow	0.00	4.44B	-2.62B	-4.38B	-2.17B	-5.97B

Alembic Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 977.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APLLTD, the sentiment is Neutral. The current price of 977.3 is above the 20-day moving average (MA) of 954.13, above the 50-day MA of 971.01, and above the 200-day MA of 941.98, indicating a neutral trend. The MACD of -0.60 indicates Negative momentum. The RSI at 49.65 is Neutral, neither overbought nor oversold. The STOCH value of 72.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:APLLTD.

Alembic Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	74 Outperform	153.59B	9.05	24.79%	0.57%	4.14%	3.72%
MARKSANS	69 Neutral	81.25B	23.21	15.43%	0.45%	16.94%	4.90%
GLAXO	66 Neutral	463.41B	48.77	47.54%	1.96%	6.65%	48.47%
JBCHEPHARM	61 Neutral	265.32B	38.48	19.21%	0.92%	11.56%	16.30%
APLLTD	60 Neutral	₹192.10B	31.85		1.15%	8.20%	-4.26%
JUBLPHARMA	56 Neutral	176.71B	38.18	13.42%	0.45%	8.12%	-16.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Alembic Pharmaceuticals Limited Corporate Events

Alembic Pharmaceuticals Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited has announced that it received final approval from the US Food & Drug Administration (USFDA) for its Tretinoin Cream USP, 0.025%, which is therapeutically equivalent to the reference drug Retin-A Cream by Bausch Health. This approval marks a significant step for Alembic, as the Tretinoin cream has an estimated market size of US$ 94 million as of June 2025, potentially enhancing the company’s market position in the treatment of acne vulgaris. With this approval, Alembic now has a cumulative total of 224 ANDA approvals, reflecting its strong capability in the generic pharmaceutical sector.

Alembic Pharmaceuticals Hosts 15th AGM Virtually, Engages Stakeholders

Alembic Pharmaceuticals Limited held its 15th Annual General Meeting on August 5, 2025, via video conferencing, adhering to the regulations set by the Companies Act, 2013, and SEBI Listing Regulations, 2015. The meeting, attended by all directors and key auditors, facilitated electronic voting for resolutions and included a statement from the Chairman & CEO, Mr. Chirayu Amin, who addressed company affairs and responded to member inquiries.

Alembic Pharmaceuticals Announces New Auditor Appointments

Alembic Pharmaceuticals Limited announced a change in its auditors following the approval at its 15th Annual General Meeting. The company appointed M/s. KKC & Associates LLP as its new Statutory Auditors and M/s. Samdani Shah & Kabra as its Secretarial Auditors, both for a term of five years. This change in auditors is part of the company’s compliance with regulatory requirements and may impact its financial reporting and governance practices.

Alembic Pharmaceuticals Announces New Auditor Appointments

Alembic Pharmaceuticals Limited announced a change in its auditors following the approval at the company’s 15th Annual General Meeting. M/s. KKC & Associates LLP has been appointed as the new Statutory Auditors, replacing M/s. K.C. Mehta & Co. LLP, for a five-year term. Additionally, M/s. Samdani Shah & Kabra has been appointed as the Secretarial Auditor for the same duration. This change in auditors is part of the company’s compliance with the SEBI Listing Regulations, potentially impacting its governance and audit processes.